1-9 of 9
Yong Mun
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results from the Phase II Morningsun Study

Ian W. Flinn, L. Elizabeth Budde, Aung M. Tun, John M. Burke, Bertrand Anz, Shachar Peles, Jeff P. Sharman, Praveen K. Tumula, Juliana M. L. Biondo, Prachi Jani, Mei Wu, Tony Lin, Neha Parmar, Yong Mun, Nai-Shun Yao, Steven Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3029.
https://doi.org/10.1182/blood-2023-177917
Published: 2023
Journal Articles

Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia

Jeff P. Sharman, MD, John M Burke, MD, Habte A Yimer, MD, Michael A. Boxer, MD, Sunil Babu, MD, Jia Li, PhD, Yong Mun, PhD, Alexey Danilov, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4317.
https://doi.org/10.1182/blood-2019-122482
Published: 2019
Journal Articles

Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)

Jennifer R. Brown, MD PhD, Matthew S. Davids, MD, Julie E Chang, MD, Shuo Ma, MD PhD, Juliana M L Biondo, MD, Yong Mun, PhD, Madlaina Breuleux, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4320.
https://doi.org/10.1182/blood-2019-123665
Published: 2019
Journal Articles

Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Final Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine

Alexey Danilov, MD PhD, Habte A Yimer, MD, Michael Boxer, MD, John M Burke, MD, Sunil Babu, MD, Jia Li, PhD, Yong Mun, PhD, Peter C Trask, PhD MPH, Anthony S Masaquel, PhD MPH, Jeff P. Sharman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3491.
https://doi.org/10.1182/blood-2019-123630
Published: 2019
Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Jacob D. Soumerai, MD, Ai Ni, PhD, Mohamed Darif, PhD, Anil Londhe, PhD, Guan Xing, PhD, Yong Mun, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Kari G. Chaffee, MS, Richard R. Furman, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jeff Sharman, MD, John F. Seymour, MBBS, PhD, Asher A. Chanan-Khan, MD, John C. Byrd, MD, Jeffrey A. Jones, MD MPH, Lucille A. Ferrante, MD, Lyndah K. Dreiling, MD, Mehrdad Mobasher, MD MPH, Thomas Stark, MD PhD, Vijay Reddy, MD PhD, Angela J. Howes, BSc, PhD, Danelle James, MD MAS, Pankaj Bhargava, MD, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4394.
https://doi.org/10.1182/blood-2018-99-112989
Published: 2018
Journal Articles

Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, MD PhD, Matthew S Davids, Julie Chang, Shuo Ma, MD PhD, Juliana Biondo, Mehrdad Mobasher, MD MPH, Yong Mun, PhD, Anthony R Mato, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5556.
https://doi.org/10.1182/blood-2018-99-116942
Published: 2018
Journal Articles

Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine

Jeffrey P. Sharman, MD, Habte Yimer, MD, Michael Boxer, MD, Nicholas Di Bella, Sunil Babu, Jia Li, PhD, Yong Mun, Peter Trask, Anthony Masaquel, MPH, PhD, Carolina M Reyes, PhD, Alexey Danilov, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 683.
https://doi.org/10.1182/blood.V130.Suppl_1.683.683
Published: 2017
Journal Articles

Evaluation of Single-Dose Palifermin To Reduce Oral Mucositis (OM) in Fractionated Total Body Irradiation (fTBI) and High Dose (HD) Chemotherapy with Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation.

Thomas C. Shea, MD, Tarun Kewalramani, MD, Yong Mun, Gerald Jayne, Lyndah K. Dreiling, MD
Journal: Blood
Blood (2006) 108 (11): 3073.
https://doi.org/10.1182/blood.V108.11.3073.3073
Published: 2006
Journal Articles

Darbepoetin alfa Maintains Hemoglobin Levels in Patients with Myelodysplastic Syndromes (MDS) after Therapeutic Interchange from Epoetin alfa: Results of a Retrospective Chart Review.

Jeffrey Patton, MD, Yong Mun, Joel Wallace
Journal: Blood
Blood (2004) 104 (11): 4708.
https://doi.org/10.1182/blood.V104.11.4708.4708
Published: 2004